We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
BWAY Shares Gain on Optum Expanding Deep TMS Coverage for Teens
Read MoreHide Full Article
Key Takeaways
BWAY benefits as Optum expands Deep TMS coverage to adolescents with major depressive disorder.
BWAY sees a wider reimbursable teen patient base, driving earlier treatment adoption and utilization growth.
BWAY gains from broader insurer alignment that improves revenue visibility and encourages clinic investment.
BrainsWay Ltd. (BWAY - Free Report) recently announced an expansion of insurance coverage for its Deep TMS therapy in adolescent depression. The update signals growing payer confidence in non-drug neurostimulation treatments and improves reimbursement visibility for a younger patient population.
The development follows Optum Behavioral Health expanding its medical policy to include eligible adolescents, adding a meaningful number of covered lives. For investors, the decision reinforces Deep TMS’ growing clinical acceptance and supports BrainsWay’s longer-term commercial opportunity.
Likely Trend of BWAY Stock Following the News
Following the announcement, BWAY shares gained 10.1% at yesterday’s market closing. Shares of the company have climbed 53.6% in the six-month period compared with the industry’s 5.5% growth and the S&P 500's 15.1% gain.
Over the long run, the coverage expansion strengthens BrainsWay by widening its reimbursable patient base at an earlier stage of the treatment journey, improving utilization and lifetime value per system. Broader insurer alignment reduces reimbursement friction, supports more predictable revenue growth and encourages clinics to invest in Deep TMS capacity, positioning the company to build durable demand and deepen its competitive moat in non-invasive depression treatment.
BWAY currently has a market capitalization of $334.8 million. The company projects an earnings growth of 100% for the current year.
Image Source: Zacks Investment Research
More on the News
Deep TMS is a noninvasive brain stimulation therapy developed by BrainsWay that uses patented H-coil technology to stimulate deeper and broader regions of the brain associated with mood regulation. FDA-cleared for depression, including as an adjunctive treatment for adolescents, Deep TMS delivers magnetic pulses without surgery or systemic drug exposure, offering a well-tolerated option for patients who do not respond adequately to antidepressant medications.
BrainsWay announced that Optum Behavioral Health, part of UnitedHealth Group, has expanded its medical policy to cover Deep TMS™ therapy for adolescents aged 15 and older diagnosed with major depressive disorder. Optum’s network represents more than 48 million covered lives, making this one of the most meaningful single-policy expansions for BrainsWay to date. The decision reflects growing payer confidence in Deep TMS as a clinically proven, non-drug treatment option, particularly for younger patients who do not respond to or cannot tolerate traditional antidepressant medications.
Optum now joins a broad and expanding list of insurers covering Deep TMS for adolescent depression, including Evernorth Health Services, CVS/Aetna, Medi-Cal, PacificSource Health Plans, TRICARE, and several Blue Cross and Blue Shield organizations such as Health Care Service Corporation, Highmark, Regence, Florida Blue, Blue Cross Blue Shield of Michigan and Blue Cross Blue Shield of North Carolina.
Collectively, these payers cover roughly 180 million lives. The expansion is especially notable given the estimated 5 million adolescents aged 15-21 in the United States affected by major depression, a population with limited effective treatment options.
Favorable Industry Prospects for BWAY
Per a report by Grand View Research, the global neuromodulation devices market size was estimated at $5.80 billion in 2024 and is projected to reach $10.39 billion by 2030, registering a CAGR of 8.51% from 2025 to 2030.
The increasing incidence of chronic pain, neurological disorders and mental health conditions is expected to drive the demand for effective and innovative treatment solutions.
BrainsWay Advances Beyond Depression With New AUD Trial
In November, BWAY announced the launch of a multicenter clinical trial evaluating its next-generation Deep TMS 360 system for the treatment of Alcohol Use Disorder (AUD), a condition marked by high relapse rates despite existing therapies. The study represents the first multicenter trial using BrainsWay’s new multichannel TMS platform, underscoring a key milestone in expanding its clinical footprint and advancing its innovation pipeline beyond depression.
BWAY’s Zacks Rank & Key Picks
Currently, BWAY carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Intuitive Surgical (ISRG - Free Report) , Medpace Holdings (MEDP - Free Report) and Boston Scientific (BSX - Free Report) .
Intuitive Surgical, sporting a Zacks Rank #1 (Strong Buy) at present, posted a third-quarter 2025 adjusted EPS of $2.40, beating the Zacks Consensus Estimate by 20.6%. Revenues of $2.51 billion topped the Zacks Consensus Estimate by 3.9%. You can see the complete list of today’s Zacks #1 Rank stocks here.
ISRG has an estimated long-term earnings growth rate of 15.7% compared with the industry’s 11.9% growth. The company’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 16.34%.
Medpace, currently carrying a Zacks Rank #2 (Buy), reported a third-quarter 2025 EPS of $3.86, which surpassed the Zacks Consensus Estimate by 10.29%. Revenues of $659.9 million beat the Zacks Consensus Estimate by 3.04%.
MEDP has an estimated earnings growth rate of 17.1% for 2025 compared with the industry’s 16.6% growth. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 14.28%.
Boston Scientific, currently carrying a Zacks Rank #2, reported a third-quarter 2025 adjusted EPS of 75 cents, which surpassed the Zacks Consensus Estimate by 5.6%. Revenues of $5.07 billion topped the Zacks Consensus Estimate by 1.9%.
BSX has an estimated long-term earnings growth rate of 16.4% compared with the industry’s 13.5% growth. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 7.36%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Shutterstock
BWAY Shares Gain on Optum Expanding Deep TMS Coverage for Teens
Key Takeaways
BrainsWay Ltd. (BWAY - Free Report) recently announced an expansion of insurance coverage for its Deep TMS therapy in adolescent depression. The update signals growing payer confidence in non-drug neurostimulation treatments and improves reimbursement visibility for a younger patient population.
The development follows Optum Behavioral Health expanding its medical policy to include eligible adolescents, adding a meaningful number of covered lives. For investors, the decision reinforces Deep TMS’ growing clinical acceptance and supports BrainsWay’s longer-term commercial opportunity.
Likely Trend of BWAY Stock Following the News
Following the announcement, BWAY shares gained 10.1% at yesterday’s market closing. Shares of the company have climbed 53.6% in the six-month period compared with the industry’s 5.5% growth and the S&P 500's 15.1% gain.
Over the long run, the coverage expansion strengthens BrainsWay by widening its reimbursable patient base at an earlier stage of the treatment journey, improving utilization and lifetime value per system. Broader insurer alignment reduces reimbursement friction, supports more predictable revenue growth and encourages clinics to invest in Deep TMS capacity, positioning the company to build durable demand and deepen its competitive moat in non-invasive depression treatment.
BWAY currently has a market capitalization of $334.8 million. The company projects an earnings growth of 100% for the current year.
Image Source: Zacks Investment Research
More on the News
Deep TMS is a noninvasive brain stimulation therapy developed by BrainsWay that uses patented H-coil technology to stimulate deeper and broader regions of the brain associated with mood regulation. FDA-cleared for depression, including as an adjunctive treatment for adolescents, Deep TMS delivers magnetic pulses without surgery or systemic drug exposure, offering a well-tolerated option for patients who do not respond adequately to antidepressant medications.
BrainsWay announced that Optum Behavioral Health, part of UnitedHealth Group, has expanded its medical policy to cover Deep TMS™ therapy for adolescents aged 15 and older diagnosed with major depressive disorder. Optum’s network represents more than 48 million covered lives, making this one of the most meaningful single-policy expansions for BrainsWay to date. The decision reflects growing payer confidence in Deep TMS as a clinically proven, non-drug treatment option, particularly for younger patients who do not respond to or cannot tolerate traditional antidepressant medications.
Optum now joins a broad and expanding list of insurers covering Deep TMS for adolescent depression, including Evernorth Health Services, CVS/Aetna, Medi-Cal, PacificSource Health Plans, TRICARE, and several Blue Cross and Blue Shield organizations such as Health Care Service Corporation, Highmark, Regence, Florida Blue, Blue Cross Blue Shield of Michigan and Blue Cross Blue Shield of North Carolina.
Collectively, these payers cover roughly 180 million lives. The expansion is especially notable given the estimated 5 million adolescents aged 15-21 in the United States affected by major depression, a population with limited effective treatment options.
Favorable Industry Prospects for BWAY
Per a report by Grand View Research, the global neuromodulation devices market size was estimated at $5.80 billion in 2024 and is projected to reach $10.39 billion by 2030, registering a CAGR of 8.51% from 2025 to 2030.
The increasing incidence of chronic pain, neurological disorders and mental health conditions is expected to drive the demand for effective and innovative treatment solutions.
BrainsWay Advances Beyond Depression With New AUD Trial
In November, BWAY announced the launch of a multicenter clinical trial evaluating its next-generation Deep TMS 360 system for the treatment of Alcohol Use Disorder (AUD), a condition marked by high relapse rates despite existing therapies. The study represents the first multicenter trial using BrainsWay’s new multichannel TMS platform, underscoring a key milestone in expanding its clinical footprint and advancing its innovation pipeline beyond depression.
BWAY’s Zacks Rank & Key Picks
Currently, BWAY carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Intuitive Surgical (ISRG - Free Report) , Medpace Holdings (MEDP - Free Report) and Boston Scientific (BSX - Free Report) .
Intuitive Surgical, sporting a Zacks Rank #1 (Strong Buy) at present, posted a third-quarter 2025 adjusted EPS of $2.40, beating the Zacks Consensus Estimate by 20.6%. Revenues of $2.51 billion topped the Zacks Consensus Estimate by 3.9%. You can see the complete list of today’s Zacks #1 Rank stocks here.
ISRG has an estimated long-term earnings growth rate of 15.7% compared with the industry’s 11.9% growth. The company’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 16.34%.
Medpace, currently carrying a Zacks Rank #2 (Buy), reported a third-quarter 2025 EPS of $3.86, which surpassed the Zacks Consensus Estimate by 10.29%. Revenues of $659.9 million beat the Zacks Consensus Estimate by 3.04%.
MEDP has an estimated earnings growth rate of 17.1% for 2025 compared with the industry’s 16.6% growth. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 14.28%.
Boston Scientific, currently carrying a Zacks Rank #2, reported a third-quarter 2025 adjusted EPS of 75 cents, which surpassed the Zacks Consensus Estimate by 5.6%. Revenues of $5.07 billion topped the Zacks Consensus Estimate by 1.9%.
BSX has an estimated long-term earnings growth rate of 16.4% compared with the industry’s 13.5% growth. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 7.36%.